![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
Sponsored by: |
GlaxoSmithKline |
---|---|
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00474266 |
The purpose of this study is to demonstrate, in 12-23 month old children, the non-inferiority of the meningococcal vaccine 134612 given with Priorix-Tetra™. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
Condition | Intervention | Phase |
---|---|---|
Meningococcal Serogroup A, C, W-135, Y Diseases Measles Mumps Rubella Varicella |
Biological: Meningococcal vaccine GSK134612 Biological: Meningitec™ Biological: Priorix-Tetra™ |
Phase III |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Open Label, Parallel Assignment, Efficacy Study |
Official Title: | Immunogenicity & Safety Study of GSK Biologicals' Meningococcal Vaccine GSK134612 When co-Administered With GSK Biologicals' MMRV Vaccine (Priorix-Tetra™) in Healthy 12 to 23-Month-Old Children |
Enrollment: | 1000 |
Study Start Date: | June 2007 |
Study Completion Date: | February 2008 |
Primary Completion Date: | February 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Group C: Active Comparator
Priorix-Tetra™, followed by Meningitec™ 42 days later and the second dose of Priorix-Tetra™ 84 days later
|
Biological: Meningitec™
Single dose intramuscular injection
Biological: Priorix-Tetra™
2-dose subcutaneous injection
|
Group D: Active Comparator
Meningitec™, followed by 2 doses of Priorix-Tetra™, respectively 42 and 84 days later
|
Biological: Meningitec™
Single dose intramuscular injection
Biological: Priorix-Tetra™
2-dose subcutaneous injection
|
Group B: Experimental
Meningococcal vaccine GSK134612, followed by 2 doses of Priorix-Tetra™, respectively 42 and 84 days later
|
Biological: Meningococcal vaccine GSK134612
Single dose intramuscular injection
Biological: Priorix-Tetra™
2-dose subcutaneous injection
|
Group A: Experimental
Meningococcal vaccine GSK134612 + Priorix-Tetra™, followed by the second dose of Priorix-Tetra™ 84 days later
|
Biological: Meningococcal vaccine GSK134612
Single dose intramuscular injection
Biological: Priorix-Tetra™
2-dose subcutaneous injection
|
Open multicentre study with 4 treatment groups. Two groups will receive the 134612 vaccine with Priorix-Tetra™ either at the same or different visits followed by a second Priorix-Tetra™ vaccination at 84 days.
Two control groups will receive Priorix-Tetra™ and Meningitec™ at different visits followed by a second Priorix-Tetra™ vaccination at 84 days.
For all subjects, two blood samples will be taken: prior to and 42 days after the first vaccination. In a subset (30% of subjects in Groups A en C) from selected study centres: additional sample 42 days after second Priorix-Tetra™ dose.
Ages Eligible for Study: | 12 Months to 23 Months |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | GSK ( Study Director ) |
Study ID Numbers: | 109670 |
Study First Received: | May 15, 2007 |
Last Updated: | October 27, 2008 |
ClinicalTrials.gov Identifier: | NCT00474266 History of Changes |
Health Authority: | Finland: Ministry of Social Affairs and Health |
meningococcal vaccine MMRV vaccine immunogenicity conjugate vaccine co-administration |
Virus Diseases Herpes Zoster Measles Chickenpox DNA Virus Infections |
Healthy Rubella Mumps Herpesviridae Infections |
Virus Diseases Chickenpox DNA Virus Infections Herpesviridae Infections |